2025 Brings Major Breakthroughs in Asthma Treatment—Here's What Changed

2025 marked a pivotal year for asthma care, with the Food and Drug Administration (FDA) approving groundbreaking treatments that offer new hope for millions of Americans struggling with breathing difficulties. The year brought the first ultra-long-acting biologic requiring only twice-yearly injections, expanded rescue therapy options, and promising oral medications that could revolutionize how we treat this chronic respiratory condition.

What New Asthma Medications Were Approved in 2025?

The FDA made several landmark approvals that expanded treatment options across the asthma severity spectrum. The most notable was depemokimab-ulaa (Exdensur), the first ultra-long-acting biologic for severe eosinophilic asthma in patients 12 and older. Unlike current biologics that require monthly or bi-weekly injections, this medication only needs to be administered twice per year.

The approval was supported by data from two major phase 3 trials called SWIFT-1 and SWIFT-2, which demonstrated significant reductions in yearly asthma attacks compared to placebo while maintaining a safety profile similar to standard treatments. This breakthrough could dramatically improve treatment adherence for patients who struggle with frequent injections.

Additionally, the FDA expanded the label for albuterol/budesonide (Airsupra) to include adults with mild asthma. Based on results from the phase 3b BATURA trial, this anti-inflammatory rescue therapy reduced the risk of severe exacerbations by nearly 50% compared to regular albuterol and lowered annual steroid use.

How Are Oral Treatments Changing Asthma Care?

Perhaps the most exciting development was the advancement of oral asthma medications, which could offer patients a more convenient alternative to inhalers and injections. Dexpramipexole showed significant improvements in lung function and reduced eosinophil levels in people with eosinophilic asthma during its phase 3 EXHALE-4 study. If approved, it would become the first oral treatment specifically for eosinophilic asthma.

The FDA also cleared an investigational new drug application for frevecitinib (KN-002), a novel inhaled dry powder therapy designed for patients whose asthma remains poorly controlled despite standard maintenance treatments. This represents a new approach to targeting inflammation directly in the airways.

What Role Does Air Quality Play in Respiratory Health?

While new treatments offer hope, environmental factors continue to significantly impact asthma management. The American Lung Association's latest State of the Air report revealed that nearly half of Americans live in areas with unhealthy air quality, with worsening ozone and particle pollution driven partly by heat and wildfires threatening respiratory health.

Air pollution, both outdoor and indoor, remains a major risk factor for respiratory disease. Chronic obstructive pulmonary disease (COPD) is the most common cause of respiratory deaths attributable to air pollution exposure, followed by asthma. Almost 14% of chronic respiratory deaths in European Environment Agency member countries are due to air pollution, with the highest rates in southeastern and eastern Europe.

Key air pollutants that contribute to respiratory disease include:

• Particulate Matter (PM): Tiny particles that can penetrate deep into the lungs and cause immediate inflammation and oxidative stress
• Nitrogen Oxides (NOx): Gases primarily from vehicle emissions that can trigger asthma symptoms and worsen existing conditions
• Ozone (O3): Ground-level ozone that forms from other pollutants and can cause respiratory symptoms even in healthy individuals

Research shows that long-term exposure to these pollutants, including PM2.5, PM10, and nitrogen dioxide (NO2), increases the risk of developing COPD, particularly in individuals with high genetic risk and unhealthy lifestyles. The same pollutants also increase asthma risk, especially in children, where each 1 microgram per cubic meter increase in PM2.5 concentrations is associated with a 3% increase in asthma development risk.

Beyond pharmaceutical advances, 2025 also highlighted the importance of comprehensive care approaches. Clinical trials demonstrated that pulmonary rehabilitation could meaningfully reduce airway inflammation in people with asthma who had elevated fractional exhaled nitric oxide (FeNO) levels, with the high-FeNO group experiencing a 40% drop during a 3-week program.

These developments collectively represent a shift toward precision, inflammation-driven management that considers both pharmaceutical interventions and environmental factors. As wildfire frequency and severity continue to rise worldwide, integrating air quality considerations with advanced treatments will be crucial for optimal asthma management.